Who Paid My Doc
Natpara (Parathyroid Hormone)
Drug Internal Medicine
NDC 68875-0202-2
General payments
$735,048
Research payments
$2,536,293
Through program year 2024, $735,048 in general payments and $2,536,293 in research payments were reported against Natpara (Parathyroid Hormone) (Internal Medicine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $11,599 | 5 |
| 2024 | Research | $1,050 | 1 |
| 2023 | General | $12,028 | 8 |
| 2023 | Research | $64,000 | 58 |
| 2022 | General | $22,009 | 40 |
| 2022 | Research | $298,786 | 210 |
| 2021 | General | $47,926 | 22 |
| 2021 | Research | $425,536 | 207 |
| 2020 | General | $23,476 | 30 |
| 2020 | Research | $659,944 | 189 |
| 2019 | General | $618,011 | 5,679 |
| 2019 | Research | $1,086,977 | 271 |
Breakdown
Each share is of general payments naming this product in 2024.
Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2024 where a state was reported.
Records
5,784 general · 936 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.